Patents by Inventor Jeffrey W. Pollard

Jeffrey W. Pollard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITION OF MACROPHAGE-SYNTHESIZED WNT7B TO INHIBIT TUMOR ANGIOGENESIS AND METASTASIS
    Publication number: 20140370027
    Abstract: The present invention provides methods of inhibiting angiogenesis in a malignant tumor, inhibiting metastasis of a malignant tumor and of inhibiting transformation of a benign tumor to a malignant tumor. The present invention also provides assays for identifying inhibitors of angiogenesis in a malignant tumor, inhibitors of metastasis of a malignant tumor and of inhibitors of transformation of a benign tumor to a malignant tumor.
    Type: Application
    Filed: March 30, 2012
    Publication date: December 18, 2014
    Applicants: Cincinnati Childrens's Hospital Medical Center, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Jeffrey W. Pollard, Richard A. Lang
  • Method for inhibiting metastasis by using anti-CCL3 antibodies
    Patent number: 8716235
    Abstract: Methods and compositions are provided for inhibiting metastasis of a tumor in a subject, or of inhibiting progression of a primary tumor in a subject which requires macrophages for progression.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: May 6, 2014
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Jeffrey W. Pollard
  • MACROPHAGE-SYNTHESIZED CCL3 PROMOTES BREAST CANCER METASTASIS
    Publication number: 20130280254
    Abstract: Methods and compositions are provided for inhibiting metastasis of a tumor in a subject, or of inhibiting progression of a primary tumor in a subject which requires macrophages for progression.
    Type: Application
    Filed: April 10, 2013
    Publication date: October 24, 2013
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Jeffrey W. Pollard
  • Methods for identifying compounds which modulate the activity of MSH5
    Patent number: 7211375
    Abstract: An animal, e.g., transgenic mouse, in which the MSH5 gene is misexpressed. The animal is useful for screening treatments for a number of conditions. Methods for identifying contraceptive agents are also described.
    Type: Grant
    Filed: September 11, 2000
    Date of Patent: May 1, 2007
    Assignees: Dana-Farber Cancer Institute, Inc., Albert Einstein College of Medicine of Yeshiva University
    Inventors: Winfried Edelmann, Richard D. Kolodner, Jeffrey W. Pollard, Raju S. Kucherlapati
  • Methods for identifying contraceptive compounds
    Patent number: 6794147
    Abstract: An animal, e.g., transgenic mouse, in which the MSH4 gene is misexpressed. The animal is useful for screening treatments for a number of conditions. Methods for identifying contraceptive agents are also described.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: September 21, 2004
    Assignees: Wyeth, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Jeffrey W. Pollard, Winfried Edelmann, Paula E. Cohen, Burkhard Kneitz, Panos Stevis, Raju S. Kucherlapati
  • MSH5 ablated mice and uses therefor
    Patent number: 6444873
    Abstract: An animal, e.g., transgenic mouse, in which the MSH5 gene is misexpressed. The animal is useful for screening treatments for a number of conditions. Methods for identifying contraceptive agents are also described.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: September 3, 2002
    Assignees: Albert Einstein College of Medicine of Yeshiva University, Dana-Farber Cancer Institute, Inc.
    Inventors: Winfried Edelmann, Richard D. Kolodner, Jeffrey W. Pollard, Raju S. Kucherlapati